GHAM
TEVA icon

Gilman Hill Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Gilman Hill Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,168
Closed -$223K – 195
2016
Q1 		$223K Buy
+4,168
New +$245K 0.1% 150

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gilman Hill Asset Management's TEVA Position: Q2 2016 in Review

Gilman Hill Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 4,168 shares — an estimated $223K sold.

Gilman Hill Asset Management first reported a position in TEVA in Q1 2016 and held it in 1 quarter. The position peaked at $223K in Q1 2016. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Gilman Hill Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Gilman Hill Asset Management sold 4,168 Teva Pharmaceuticals shares in Q2 2016, an estimated $223K.
  • Gilman Hill Asset Management first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Gilman Hill Asset Management's Teva Pharmaceuticals position peaked at $223K in Q1 2016.
  • 812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Gilman Hill Asset Management's 13F filing for Q2 2016, filed 22 Jul 2016.